Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-SATB2 mRNAs with seed-region complementarity refers to a heterogeneous group of messenger RNA (mRNA) molecules that contain sequences matching the seed region of microRNAs (miRNAs) that also target the Special AT-rich sequence-binding protein 2 (SATB2). SATB2 is a critical transcription factor involved in craniofacial patterning, osteoblast differentiation, and neuronal development, and its dysregulation is linked to Glass syndrome and various cancers (UniProt Q9UPW6). Because miRNA-target recognition is primarily driven by a 6-8 nucleotide seed sequence, any mRNA possessing a complementary site can be suppressed by the same miRNA (Bartel, Cell, 2009). In the context of miRNA-based research or therapeutics aimed at SATB2, these non-SATB2 transcripts represent potential off-targets or co-regulated genes. Unintended silencing of these mRNAs can lead to complex phenotypic outcomes, off-target toxicity, or the masking of specific therapeutic effects (PubMed: 21933825). Consequently, identifying and monitoring these molecules is essential for evaluating the specificity and safety of RNA interference (RNAi) or miRNA-modulating strategies.
MicroRNA-mediated gene silencing via the RNA-induced silencing complex (RISC), which involves seed-region pairing to the 3' untranslated region (UTR) of target mRNAs, leading to translational repression or transcript degradation (Bartel, Cell, 2009).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-SATB2 mRNAs with seed-region complementarity.